DEF 14A: Avantor Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Governance and Compensation Matters

Avantor's 2025 proxy statement details the agenda for the annual stockholders meeting, including director elections, auditor ratification, and executive compensation approval.

Summary

• Avantor will hold its Annual Meeting of Stockholders on May 8, 2025, as a virtual meeting.
• Stockholders of record as of March 14, 2025, are eligible to vote on key proposals.
• The agenda includes the election of ten directors for a one-year term, ratification of Deloitte & Touche LLP as the independent auditor, and an advisory vote on executive compensation.
• The Board of Directors recommends voting for all director nominees, ratifying the auditor, and approving executive compensation.
• In 2024, Avantor implemented a new operating model and achieved free cash flow conversion of over 110%.
• The company's sustainability efforts include reducing Scope 1 and 2 emissions and expanding the Responsible Supplier Program.
• Executive compensation is designed to align with long-term business outcomes and strong governance practices.
• The Compensation and Human Resources Committee uses a peer group to benchmark executive compensation.
• The company has stock ownership guidelines for directors and officers to align their interests with those of stockholders.

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both achievements and ongoing efforts. The tone is positive, emphasizing growth, sustainability, and alignment with stockholder interests. However, the inclusion of risk factors and the mention of a slight decrease in revenue target temper the overall optimism.

Positives

• Avantor implemented a new operating model based around two global segments laboratory solutions and bioscience production while transforming its cost structure.
• The Company executed on its cost savings initiatives ahead of schedule in 2024 and delivered free cash flow conversion of over 110%.
• The company achieved a Total Recordable Incident Rate (TRIR) of 0.34, continuing to place us in the top quartile for safety performance in our relevant industries.
• Associates volunteered more than 18,000 hours at our corporate sponsored events or through our Dollars for Doers and Volunteer Time Off benefits, representing an increase of over 85% from prior year.
• The company received 93% stockholder support on our 2024 Say-on-Pay proposal.

Risks

• The document mentions forward-looking statements are subject to risks and uncertainties, including those described in the company's Annual Report on Form 10-K.

Future Outlook

The company is well-positioned to capitalize on improving market trends and is committed to delivering sustainable value to customers and stockholders.

Management Comments

• Jonathan Peacock, Chairman: 'This is truly the golden age of science, and Avantor is proud to be an integral part of the breakthrough therapies that are changing lives for patients.'
• Jonathan Peacock, Chairman: 'We value our continued dialogue with our stockholders and consider the feedback we receive as an important input to our decision-making process.'

Industry Context

Avantor is positioned as a leading global partner for laboratory consumables, bioprocessing materials, and medical-grade silicone formulations, with a significant portion of its business in biopharma and healthcare.

Comparison to Industry Standards

• The company benchmarks executive compensation against a peer group including Agilent Technologies, Baxter International, and Biogen Inc.
• The company also uses a reference group of industry competitors including AbbVie Inc., Cencora, Inc., and McKesson Corporation to monitor program designs and trends comparisons.
• The company's TRIR of 0.34 places it in the top quartile for safety performance in its relevant industries.

Corporate Governance

Related Party Transactions

• The Board reviewed overall spending with Tessera Therapeutics, where Dr. Severino serves a Chief Executive Officer, GRAIL, Inc., where Mr. Summe serves as the chair of the board, UCB, where Mr. Peacock serves as the chair of the board, and the University of California San Diego, where Dr. Carethers serves as the Vice Chancellor for Health Sciences.

Stakeholder Impact

• The company is committed to delivering sustainable value to customers and stockholders.
• The company's sustainability strategy aims to foster an inclusive work environment, promote innovation for a sustainable future, support and strengthen our communities, and add value to Avantor.

Next Steps

• Stockholders are encouraged to vote by proxy in advance of the Annual Meeting.
• The Board of Directors will consider the outcome of the advisory vote on executive compensation when making future compensation decisions.

Key Dates

Keywords

stockholders meeting, proxy statement, executive compensation, corporate governance, director elections, sustainability, financial performance, Avantor